Form 4: Collegium Pharmaceutical Director McFarlane Receives Stock Grant

Director Neil F. McFarlane of Collegium Pharmaceutical, Inc. was granted 7,693 restricted stock units (RSUs) on May 16, 2024.

Summary

• Neil F. McFarlane, a director at Collegium Pharmaceutical, Inc., received a grant of 7,693 restricted stock units (RSUs) on May 16, 2024.
• Each RSU represents the right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on May 16, 2025, contingent upon McFarlane's continued service as a director.
• The RSUs will be settled in shares of common stock on the vesting date or, at the director's election, upon earlier termination of service, death, disability, or a change in control of the Issuer.
• Following the transaction, McFarlane beneficially owns 49,365 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 7

Explanation: The document indicates a standard practice of granting stock to a director, which is generally viewed positively as it aligns interests. There are no immediate negative implications.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Risks

• The value of the RSUs is subject to the market price of Collegium Pharmaceutical's common stock, which can fluctuate.

Future Outlook

The director's continued service is tied to the vesting of the RSUs, suggesting an expectation of ongoing involvement with the company.

Industry Context

Stock grants to directors are a common practice to align their interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.

Key Dates